Single centre experience of efficacy and toxicity of reduced-dose melphalan conditioning (140 mg/m2 or 110 mg/m2) in autologous stem cell transplantation for multiple myeloma

被引：0
|
作者：
Troy-Barnes, E. [1 ]
Melotti, D. [1 ]
Camilleri, M. [1 ]
Horder, J. [1 ]
Newrick, F. [1 ]
Marfil, J. [1 ]
Lee, L. [2 ]
Mahmood, A. S.
Wisniowski, B.
Papanikolaou, X. [1 ]
Wechalekar, A. [3 ]
Sive, J. [1 ]
Popat, R. [4 ]
Yong, K. [2 ]
Rabin, N. [1 ]
Kyriakou, C. [1 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, London, England
[2] UCL, Inst Canc, London, England
[3] UCL, Ctr Amyloidosis & Acute Phase Prot, London, England
[4] Univ Coll London Hosp, Clin Res Facil, Natl Inst Hlth Res, London, England
来源：
BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P146
引用
收藏
页码：178 / 179
页数：2
相关论文
共 50 条
  • [41] Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation
    Tjards, Sarah
    High, Robin
    Lunning, Matthew A.
    Wildes, Tanya M.
    Vose, Julie M.
    Baljevic, Muhamed
    Holstein, Sarah A.
    D'Angelo, Christopher R.
    BLOOD, 2023, 142
  • [42] Transplant outcomes after topotecan-melphalan-cyclophosphamide (TMC) conditioning for autologous stem cell transplantation for multiple myeloma. comparison to melphalan 200 mg/M2 (MEL200).
    Donato, M
    Aleman, A
    Weber, D
    Wang, M
    Qazilbasch, M
    Davis, M
    Roden, L
    Mendoza, F
    Champlin, R
    Giralt, S
    BLOOD, 2005, 106 (11) : 344A - 344A
  • [43] In myeloma patients treated with melphalan 100mg/m2 or melphalan 200mg/m2 outcome is not significantly different.
    Palumbo, A
    Triolo, S
    Bringhen, S
    Rus, C
    Omedè, P
    Bertola, A
    Giaccone, L
    Bianchi, A
    Bruno, B
    Tarella, C
    Caravita, T
    Musto, P
    Amadori, S
    Carotenuto, M
    Pileri, A
    Boccadoro, M
    BLOOD, 2000, 96 (11) : 419A - 419A
  • [44] Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma
    Shuai, Su
    Xu, Bin
    Li, Chunrui
    Wang, Di
    Tong, Xiwen
    Zhu, Yi
    Mao, Xia
    Xiao, Min
    Zhang, Donghua
    BLOOD, 2024, 144 : 7062 - 7063
  • [45] Salvage treatment with melphalan 100 mg/m2 in fulminant progression of multiple myeloma
    Hajek, R.
    Krejci, M.
    Krivanova, A.
    Pour, L.
    Adam, Z.
    Zahradova, L.
    Vetesnikova, E.
    Mayer, J.
    Vorlicek, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 95 - 96
  • [46] Long-term follow-up of myeloma patients treated with 140 MG/M2 melphalan without autologous transplantation.
    Powles, R
    Cunningham, D
    Gore, M
    Kulkarni, S
    Ramiah, V
    Mehta, J
    BONE MARROW TRANSPLANTATION, 1998, 21 : S210 - S210
  • [47] Triple transplantation of autologous peripheral blood stem cells each time following conditioning with 100 mg/m2 of melphalan for multiple myeloma patients in poor performance status
    Rokicka, M
    Urbanowska, E
    Torosian, T
    Dwilewicz-Trojaczek, J
    Awedan, A
    Paluszewska, M
    Wiktor-Jedrzejczak, W
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (06) : 2352 - 2354
  • [48] Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
    Moreau, P
    Facon, T
    Attal, M
    Hulin, C
    Michallet, M
    Maloisel, F
    Sotto, JJ
    Guilhot, F
    Marit, G
    Doyen, C
    Jaubert, A
    Fuzibet, JG
    François, S
    Benboubker, L
    Monconduit, M
    Voillat, L
    Macro, M
    Berthou, C
    Dorvaux, V
    Pignon, B
    Rio, B
    Matthes, T
    Casassus, P
    Caillot, D
    Najman, N
    Grosbois, B
    Bataille, R
    Harousseau, JL
    BLOOD, 2002, 99 (03) : 731 - 735
  • [49] EXCELLENT LONG-TERM OUTCOME OF AUTOLOGOUS TRANSPLANTATION WITH INTERMEDIATE-DOSE INTENSIVE MELPHALAN (100 MG/M2, MEL100) FOR MULTIPLE MYELOMA: A SINGLE CENTRE STUDY
    Fukushima, K.
    Sudo, T.
    Tamaki, T.
    HAEMATOLOGICA, 2015, 100 : 612 - 612
  • [50] Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
    Palumbo, Antonio
    Bringhen, Sara
    Bruno, Benedetto
    Falcone, Antonietta Pia
    Liberati, Anna Marina
    Grasso, Mariella
    Ria, Roberto
    Pisani, Francesco
    Cangialosi, Clotilde
    Caravita, Tommaso
    Levi, Anna
    Meloni, Giovanna
    Nozza, Andrea
    Pregno, Patrizia
    Gabbas, Attilio
    Callea, Vincenzo
    Rizzo, Manuela
    Annino, Luciana
    De Stefano, Valerio
    Musto, Pellegrino
    Baldi, Ileana
    Cavallo, Federica
    Petrucci, Maria Teresa
    Massaia, Massimo
    Boccadoro, Mario
    BLOOD, 2010, 115 (10) : 1873 - 1879
12345